IPP Bureau
Rusan Pharma achieves GMP approvals from TGA (Australia) and ANVISA (Brazil) for its manufacturing facility in Kandla SEZ
By IPP Bureau - December 17, 2024
The TGA approval marks a pivotal step in Rusan Pharma’s expansion into the Australian market
Merck announces FDA acceptance of biologics license application for Clesrovimab
By IPP Bureau - December 17, 2024
An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season
Kiran Mazumdar-Shaw honored by ISQ with ‘Jamsetji Tata Award’ for pioneering biosciences movement
By IPP Bureau - December 16, 2024
Kiran Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman & Managing Director, TQM International
Jitendra Singh releases landmark RSSDI study ' Indian Prevention of Diabetes Study (IPDS) on Yoga and Diabetes Prevention'
By IPP Bureau - December 16, 2024
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS
By IPP Bureau - December 16, 2024
Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS
Aster DM Healthcare launches precision oncology, offering data-driven, personalized cancer care
By IPP Bureau - December 16, 2024
Harnessing advanced data analysis for early detection, prevention and better outcomes
Gilead Sciences appoints Dietmar Berger as Chief Medical Officer
By IPP Bureau - December 14, 2024
Dr. Berger is a board-certified internist, hematologist and oncologist who brings more than 25 years of extensive experience in developing and delivering innovative medicines
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
By IPP Bureau - December 14, 2024
Final decision from the European Commission is anticipated within the coming months
Lupin acquires 3 Trademarks from Boehringer Ingelheim for diabetes portfolio
By IPP Bureau - December 14, 2024
The trademark rights for these brands will be transferred to Lupin by March next year.
CuraTeQ Biologics receives positive opinion for biosimilar Zefylti
By IPP Bureau - December 14, 2024
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
Pfizer announces Phase 3 PATINA study in patients with HR+, HER2+ metastatic breast cancer
By IPP Bureau - December 13, 2024
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
Lonza outlines strategy, new organizational structure and guidance
By IPP Bureau - December 12, 2024
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Brenntag Specialties engages Esprit Care for its Southeast Asia nutraceutical market expansion
By IPP Bureau - December 12, 2024
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Lynparza demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase 3 trial
By IPP Bureau - December 12, 2024
First and only PARP inhibitor to improve overall survival in early breast cancer
AbbVie completes acquisition of Aliada Therapeutics
By IPP Bureau - December 12, 2024
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
